Evidence map›Paper›PMID 35382637›Full record

SynthesisLupus2022

COVID-19 in patients with systemic lupus erythematosus: A systematic review.

Xue-Lei Fu, Yan Qian, Xiao-Hong Jin, Hai-Rong Yu, Lin Du, Hua Wu, Hong-Lin Chen, Ya-Qin Shi

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in Lupus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xue-Lei FuSchool of Medicine, 66479Nantong University, Nantong, Jiangsu, China.
Yan Qian74567Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Xiao-Hong Jin74567Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Hai-Rong Yu74567Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Lin DuSchool of Medicine, 66479Nantong University, Nantong, Jiangsu, China.
Hua WuSchool of Medicine, 66479Nantong University, Nantong, Jiangsu, China.
Hong-Lin ChenSchool of Public Health, 66479Nantong University, Nantong, Jiangsu, China.ORCID https://orcid.org/0000-0003-0147-6863
Ya-Qin ShiSchool of Medicine, 66479Nantong University, Nantong, Jiangsu, China.
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objectives of the study were to review the articles to identify (a) the epidemiology of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19); (b) the clinical characteristics of SLE patients with COVID-19; (c) the treatment of COVID-19 in SLE patients; and (d) the impact of COVID-19 pandemic on SLE patients. PubMed was systematically reviewed for literature published from December 2019 to June 2021. Our search was limited to human studies, with language restriction of English. Studies were included if they reported COVID-19 in SLE patients. Our systematic review included 52 studies. The prevalence of COVID-19 infection ranged from 0.0% to 18.1% in SLE patients, and the hospitalisation rates ranged from 0.24% to 10.6%. COVID-19 infection is likely to mimic SLE flare. Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic. The pandemic had a significant effect on mental and physical health. Adequate healthcare access, along with containment policies, social distancing measures and psychological nursing was required.

Indexed as

COVID-19Lupus Erythematosus, SystemicHumansHydroxychloroquinePandemicsHydroxychloroquineCOVID-19SARS-CoV-2SLESystematic Review

Identifiers

PMID35382637
PMCPMC8990101
OpenAlexW4223543686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.